Zyprexa news | Breaking Zyprexa news | Zyprexa

Eli Lilly Looks Unlikely To Outperform In 2006

... The Morgan Stanley research analyst reiterated a price target of $60 and said she does not expect the stock to outperform over the next 12 months.

"While Lilly's outlook is more favorable than that of most of its U.S.

peers, especially Bristol-Myers Squibb (nyse: BMY - news - people ), Merck (nyse: MRK - news - people ) and Pfizer (nyse: PFE - news - people ), which all face near-term patent expirations, the stock already trades at a premium to the other U.S.

names, with the exception of Bristol-Myers.

"If management's bullish top-line projections are not met, which was the case in 2005, the stock could continue to languish." 1 of 1 E-mail RSS '); //- Free Trial Issue of Forbes Forbes Gift Subscription Subscribe To Newsletters Subscriber Customer Service CEO Book Club more > Book Review Without A Dinar To Your Name Book Review When Employees Attack Michael Maiello "Going Postal" takes aim at workplace shootings.

Search Books Title Author Item Number All Fields Advanced Search New & Notable Beginner Stock Trading Online Option Trading Online Stock Trading Option Trading System Stock Market Trading Stoc...

Lilly raises profit forecast for 2006

...Lilly has just announced that it has filed for approval to extend the indications for Cymbalta to include generalized anxiety disorder.Meanwhile, the decline in sales of Lilly now says its goals are 'to further stabilise US Sales next year are expected to increase 7%-9% to more than $15 billion.Taurel also pointed to the fact that Lilly has no other major drugs due to lose patent protection for the remainder of the decade, while nine new product launches since 2001 will produce 18% of 2005 revenue and about 24% in 2006.The company also said it expects to submit five new products for approval in the next four years, as well as seeking new indications for existing products.

The lead projects are: prasugrel for acute coronary syndromes, due to be filed in the s...

Mix of pills merits a review

... Since he retired, his memory is getting worse, and he sometimes seems almost like a zombie.

I worry that his pills are hurting more than helping.

ADVERTISEMENT Combining a sedative such as diazepam (Valium) with an anti-psychotic such as Such a combination could also increase his risk of a fall.

As people age, they become more susceptible to some drug side effects.

Please ask his doctor to review his medications.

My cardiologist tells me I must take aspirin to prevent a heart attack or stroke.

He said to avoid ibuprofen and naproxen for pain relief.

Why?

Pain relievers such as ibuprofen and naproxen may interfere with the anti-clotting action of aspirin (New England Journal of Medicine, Dec.

1, 2005).

Joe Graedon, a pharmacologist, and Teresa Graedon, an expert in medical anthropology and nutrition, can be reached at http://www.peoplespharmacy.com or care of this ne...

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 | 99 | All news

Medicine   Health and Fitness